Egg-Derived Phosphatidylcholine Trial Finds Modest TMAO Response

What the Trial Tested

Researchers assessed, for the first time, the effect of long-term egg-derived phosphatidylcholine intake on serum trimethylamine N-oxide (TMAO) concentrations in healthy Japanese middle-aged and older adults. The 32 participants were divided into four groups by daily phosphatidylcholine intake: placebo (0 g), low-dose (0.3 g), medium-dose (1.0 g), and a high-dose group, over 12 weeks.

The study was published in Lipids in Health and Disease.

Findings

Twelve weeks of egg-derived phosphatidylcholine supplementation did not produce serum TMAO concentrations approaching clinically concerning levels under the tested conditions. The authors suggest egg-derived phosphatidylcholine may serve as a dietary choline source without inducing a substantial elevation in TMAO in this population.

The results are specific to the studied dose range and population and should not be generalized to other choline or lecithin forms.

Buyer Takeaway

TMAO is a frequent discussion point when buyers compare choline sources such as lecithin, phosphatidylcholine, and egg-derived ingredients. This single trial adds population-specific data but does not settle the broader TMAO question, so buyers should keep dose, form, and metabolic context in mind during ingredient qualification.

Nutranexa does not supply egg-derived phosphatidylcholine and reports the study without endorsing its conclusions.

المصادر

• Association between egg-derived phosphatidylcholine intake and trimethylamine N-oxide and atherosclerotic markers in healthy middle-aged and older adults: a randomized controlled trial
• Association between egg-derived phosphatidylcholine intake and trimethylamine N-oxide